Acorda Therapeutics, Inc. was a big mover last session, as its shares rose almost 21% on the day. The stock gained after the company reported that its Parkinson's disease drug, CVT-301 improved motor function in a late-stage trial. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $19.60 to $21.95 in the past one-month time frame.

The company has seen four positive estimate revisions over the past 30 days. Also, its Zacks Consensus Estimate moved higher over the same timeframe, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Acordacurrently carries a Zacks Rank #3 (Hold), while its Earnings ESP is positive.

Acorda Therapeutics, Inc. Price

 

Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote

A better-ranked stock in the Medical-Biomedical and Genetics space is Cellectis S.A. (CLLS Quick QuoteCLLS - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ACOR going up? Or down? Predict to see what others think: Up or Down

Zacks' Top 10 Stocks for 2017

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?

Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank.Be among the very first to see it>>